Expand SNGX Menu
SNGX MENU

SNGX Latest Press Releases

-- April 2, 2026 --

Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy PRNewswire 7:30 AM

-- March 31, 2026 --

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results PRNewswire 7:30 AM

-- March 26, 2026 --

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behet's Disease PRNewswire 7:30 AM

-- March 23, 2026 --

HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 PRNewswire 7:30 AM

-- March 19, 2026 --

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. Globe Newswire 8:00 AM
Soligenix Announces HyBryte Clinical Summary Published in "Expert Opinion on Investigational Drugs" PRNewswire 7:30 AM

-- March 10, 2026 --

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency PRNewswire 7:30 AM

-- February 26, 2026 --

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behet's Disease PRNewswire 7:30 AM

-- February 24, 2026 --

Soligenix to Present at BIO Investment & Growth Summit PRNewswire 7:30 AM

-- February 12, 2026 --

Soligenix Details Recent Progress and Upcoming Milestones PRNewswire 7:30 AM

-- January 23, 2026 --

DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event ACCESS Newswire 2:51 PM

-- December 18, 2025 --

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behet's Disease Published in Rheumatology (Oxford) PRNewswire 7:30 AM

-- December 17, 2025 --

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis PRNewswire 7:30 AM

-- December 10, 2025 --

NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease Globe Newswire 8:30 AM

-- December 5, 2025 --

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad Globe Newswire 8:30 AM

-- December 4, 2025 --

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations Globe Newswire 8:30 AM

-- December 3, 2025 --

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space Globe Newswire 8:30 AM

-- December 2, 2025 --

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now Globe Newswire 8:30 AM

-- November 19, 2025 --

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma PRNewswire 7:30 AM
Market Data Delayed 15 Minutes